Back to top
more

ASLAN Pharmaceuticals (ASLN)

(Delayed Data from NSDQ)

$0.43 USD

0.43
92,059

0.00 (-0.28%)

Updated May 31, 2024 03:58 PM ET

After-Market: $0.45 +0.02 (4.97%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASLN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

ASLAN Pharmaceuticals Ltd. [ASLN]

Reports for Purchase

Showing records 81 - 100 ( 101 total )

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 81

01/15/2019

Company Report

Pages: 6

Positive Preliminary Phase 1b Data in First-Line Biliary Tract Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 82

01/14/2019

Company Report

Pages: 6

Phase 2 Gastric Cancer Trial Did Not Meet Primary Endpoint; Reiterate Buy and Reduce Price Target to $8.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 83

01/07/2019

Company Report

Pages: 11

Phase 2 Trial in AML to Start Patient Recruitment in the U.S.; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 84

01/03/2019

Company Report

Pages: 6

Global TREETOPP Trial of Varlitinib in 2nd-line BTC Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 85

12/07/2018

Company Report

Pages: 10

ASLAN003 First-in-Class DHODH Inhibitor Emerges in AML; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 86

11/26/2018

Company Report

Pages: 1

Termination of coverage

Provider: Edison Investment Research Limited

Price: .00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 87

11/09/2018

Company Report

Pages: 6

3Q18 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 88

11/06/2018

Company Report

Pages: 6

ASLAN003 Shows Early Signs of Activity in AML; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 89

10/23/2018

Company Report

Pages: 6

Promising Results in Advanced Biliary Tract and Colorectal Cancers Presented at ESMO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 90

10/18/2018

Company Report

Pages: 6

Phase 1 Trial in Atopic Dermatitis Starts Patient Recruitment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 91

09/19/2018

Company Report

Pages: 6

Enrolment for China study adjusted

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Medical - Biomedical and Genetics

Record: 92

09/18/2018

Company Report

Pages: 6

Chinese Biliary Tract Cancer Second-Line Trial Protocol Amended; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 93

08/21/2018

Company Report

Pages: 6

FDA Grants Orphan Drug Designation in Acute Myeloid Leukemia; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 94

08/13/2018

Company Report

Pages: 6

Varlitinib Phase 2 First-Line Gastric Cancer Trial Finishes Enrollment; Data by Year-End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 95

08/07/2018

Company Report

Pages: 5

2Q18 Financial Results Reported in the U.S.; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 96

08/06/2018

Company Report

Pages: 4

2Q18 Operating Results Filed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 97

07/09/2018

Company Report

Pages: 5

ASLAN004 a go for atopic dermatitis

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 98

07/03/2018

Company Report

Pages: 6

Application to Initiate ASLAN004 Clinical Testing Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 99

06/07/2018

Company Report

Pages: 6

Additional clinical support for varlitinib

Provider: EDISON INVESTMENT RESEARCH LIMITED

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: ASLAN Pharmaceuticals Ltd.

Industry: Unclassified

Record: 100

06/06/2018

Company Report

Pages: 6

April 2018 Operating Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party